New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2013
08:35 EDTBMRNBioMarin should be bought on any weakness, says RW Baird
Baird recommends taking advantage of any weakness in BioMarin following its positive announcement the BMN-701 met the criteria to advance to Phase ll/lll. The firm believes the announcement was tempered by the proposed path to registration and clinical endpoints but could still be meaningfully differentiated from its existing competitor. Shares are Outperform rated with a $63 price target.
News For BMRN From The Last 14 Days
Check below for free stories on BMRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
12:18 EDTBMRNPiper Jaffray biopharm analyst holds an analyst/industry conference call
Subscribe for More Information
September 17, 2014
07:43 EDTBMRNBofA/Merrill to hold a conference
Subscribe for More Information
September 8, 2014
07:15 EDTBMRNIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use